Femoral Head Necrosis (FHN)

Basic Overview

Femoral head necrosis is a progressive orthopedic disease caused by interruption or impairment of the blood supply to the femoral head, leading to osteocyte and bone marrow necrosis, subsequent structural damage, femoral head collapse, and eventual glenohumeral joint dysfunction. It is the leading cause of total hip arthroplasty (THA) in young and middle-aged adults.

Etiology: Classified into two main categories: traumatic FHN (caused by femoral neck fracture, hip dislocation, or hip trauma that disrupts the femoral head blood supply) and non-traumatic FHN (most commonly associated with long-term excessive alcohol intake, prolonged glucocorticoid use, decompression sickness, autoimmune diseases, and idiopathic cases).
Clinical Manifestations: Early-stage FHN is often asymptomatic. As the disease progresses, patients develop deep groin or gluteal pain exacerbated by weight-bearing, limited hip internal rotation and abduction, and antalgic gait. End-stage disease with femoral head collapse presents with persistent rest pain, severe hip dysfunction, and disability.
Diagnosis: MRI is the gold standard for early-stage diagnosis, with a sensitivity and specificity of nearly 100%. X-rays and CT scans are used for middle and late-stage assessment of femoral head collapse, subchondral fracture, and joint space narrowing. The Association Research Circulation Osseous (ARCO) staging system is the most widely used classification for disease severity.

Standard Treatment Modalities

Conservative Management: Indicated for early-stage FHN (ARCO 1-2) with small necrotic lesions. Core interventions include risk factor modification (alcohol cessation, glucocorticoid discontinuation), protected weight-bearing, pharmacotherapy (bisphosphonates, anticoagulants, lipid-lowering agents), extracorporeal shock wave therapy (ESWT), hyperbaric oxygen therapy, and structured rehabilitation.
Joint-Preserving Surgical Treatment: The first-line option for young and middle-aged patients with early to mid-stage FHN (ARCO 2-3) without femoral head collapse. Procedures include core decompression, vascularized bone grafting (e.g., free vascularized fibular graft), osteotomy, stem cell transplantation, and porous tantalum rod implantation. These procedures aim to improve femoral head perfusion, prevent collapse, and avoid or delay total hip replacement.
End-Stage Surgical Treatment: Total hip arthroplasty (THA) is indicated for patients with femoral head collapse, joint space obliteration, severe pain, and functional disability (ARCO 3-4).

Core Advantages of Treatment in China

World-Leading Joint-Preserving Treatment System

: China is the global leader in hip-preserving therapy for FHN, with the largest clinical volume and most mature staged hip-preserving protocols worldwide. Techniques such as free vascularized fibular grafting, core decompression combined with stem cell transplantation, and porous tantalum rod implantation have achieved long-term success rates on par with or exceeding leading Western centers, effectively delaying or avoiding THA in over 70% of young and middle-aged patients. This is the most distinctive advantage of Chinese orthopedic care for FHN.

Unique Integrated TCM Therapy for Early Intervention

: TCM plays an irreplaceable role in the early treatment and prevention of FHN progression in China. Oral and topical herbal medicine with blood-activating, stasis-resolving, kidney-tonifying, and bone-strengthening properties improves femoral head microcirculation, inhibits osteocyte apoptosis, and delays disease progression. Clinical studies have confirmed that integrated TCM-Western therapy has an effective rate of over 90% for early-stage FHN, a therapeutic advantage unavailable in Western countries.

High-Precision, Personalized THA for End-Stage Disease

: For end-stage FHN patients, Chinese orthopedic surgeons have mature expertise in THA, with widespread use of 3D-printed personalized prostheses, robot-assisted surgery, and prosthesis designs optimized for East Asian hip anatomy. The 10-year prosthesis survival rate in top Chinese centers exceeds 95%, equivalent to leading Western institutions, with the highest volume of THA procedures for FHN globally.

Superior Cost-Effectiveness

: The cost of hip-preserving surgery and THA in China is only 1/4 to 1/6 of that in the U.S. or European countries. High-quality domestic hip prostheses, which meet international advanced standards at half the price of imported implants, further reduce patient financial burden, with wide insurance coverage making standardized treatment accessible to the majority of patients.